Weight concerns / separate findings
Which substance has evidence for the help you want?
Extra weight may be on your mind. The studies tested different substances and health problems, so a result for one cannot establish another substance's benefit.
Where do the four substances differ most?
Extra weight can make these treatment claims sound similar, but the human findings differ. Tirzepatide and semaglutide copy gut hormones concerned with appetite and the control of blood sugar. AOD-9604 was made from part near growth hormone's end. MOTS-c occurs naturally in your body; researchers tested muscle activity and energy use after giving extra amounts.
Evidence for the substance you might receive needs to support the choice being considered.
Large human trials support approved prescription uses for tirzepatide and semaglutide [1][4][8][9][10]. The shorter AOD-9604 human tests didn't show worthwhile weight loss. People receiving the substance had side effects similar to those receiving placebo, which contained none of the substance [14]. Animals or cells received MOTS-c in the treatment experiments. A small human study measured natural blood levels without giving the substance. No human treatment benefit was established [17][18][20][21].
Talking about weight doesn't mean substances offer equal help or equal risks for you.
What was tested for each substance?
| substance | what researchers expected | who received the substance | what was measured | what remains uncertain for you |
|---|---|---|---|---|
| Tirzepatide | Copies two gut hormones involved in keeping sugar under control | Adults in large treatment trials | Weight, blood sugar and unwanted effects | Another drug copying both hormones needs tests of its own [1][3][4][5] |
| Semaglutide | Copies GLP-1, a gut hormone affecting appetite and sugar | Adults in treatment trials; a review gathered safety findings | Weight and serious problems in kidneys or the heart | Another substance cannot take semaglutide's results as proof [8][9][10][11] |
| AOD-9604 | A growth-hormone piece intended to affect fat | Animals and adults in brief tests | Animal fat use, human side effects and rabbit cartilage damage | Useful human weight loss wasn't established [12][13][14][15][16] |
| MOTS-c | May help muscles use sugar when energy is short | Animals and cells received treatment; people had only natural blood measurements | Mouse movement and muscle loss; later health problems in untreated people | The effect of treating people has no proved benefit or safety here [17][18][19][20][21] |
Did greater weight loss settle every health question?
The weight comparison excluded type 2 diabetes and selected adults who had obesity. The trial treated 751 people for 72 weeks; average changes were -20.2% with tirzepatide and -13.7% with semaglutide [1]. Both figures mean weight loss, with more average loss from tirzepatide. Your own result could be different.
Your other illnesses may call for different evidence from the amount of weight lost.
Cell experiments found unequal responses to the two gut hormones copied by tirzepatide [6]. Those tests didn't measure human hunger or unwanted effects. A different drug copying both hormones could produce different results.
Separate semaglutide trials examined serious heart and blood-vessel trouble [9] and kidney problems [8]. The selected tirzepatide studies didn't make those same comparisons. Your other health concerns need their own evidence, beyond the change in weight.
Why didn't the AOD-9604 mouse results prove human benefit?
The encouraging AOD-9604 weight results came from mice, leaving treatment help for you unproved. Some lasting fat and weight changes depended on particular hormone responses in mouse fat cells [15]. A separate experiment found more fat burning and lower mouse weight [16]. Those findings encouraged human testing.
The human trials didn't establish the worthwhile weight loss people hoped for.
Tests lasted no more than 24 weeks. Side effects were similar with the substance and with placebo containing none of the substance [14]. Further animal tests checked for harm and looked at how the body broke the substance down [13]. Rabbits had less knee-cartilage damage [12]. Neither rabbit knees nor brief safety findings establish useful weight treatment for people, or show years of safety.
Why does measuring MOTS-c differ from giving treatment?
The human blood study gave nobody extra MOTS-c, leaving treatment benefit and harm unknown. Other experiments treated mouse muscles or cells and tested responses to an energy shortage. Treated mice did better in movement tests [17][20][21]. Benefit from treating people remained unproved by those experiments.
Measuring your body's own supply can't show what an extra supply would do.
Researchers tested natural MOTS-c blood levels in 94 people on dialysis, machine cleaning of blood when kidneys fail. The blood measurements were linked with deaths or heart problems that occurred later [18]. That link cannot establish whether extra treatment helps you, harms you or has no useful effect. Side effects and removal of added MOTS-c weren't tested.
Do the same safety findings apply to all four?
Tirzepatide and semaglutide can both cause digestive complaints, but their other risks need separate checks. The review of tirzepatide combined gallbladder and bile-tube illnesses and found an increase. Bile is needed to break down fat during digestion. The pancreas gland can become swollen, an illness called pancreatitis; whether more people developed the illness remained unsettled [3]. Semaglutide's review found digestive and bile-tube problems, while some rare risks stayed uncertain [11].
You need safety findings for the substance you would receive.
In brief AOD-9604 human trials, side effects were much alike whether people received the substance or placebo containing none of the substance [14]. That can't establish safety over years. These papers provide no proved human treatment safety for MOTS-c. Being naturally present in your body doesn't establish that more would be harmless.
What can you take to a discussion with your doctor?
You can ask which people received treatment, what happened to their health and how long the researchers looked for harm. A placebo contains no tested medicine and helps check whether the medicine caused a change. Comparing two medicines answers a different question.
The direct weight trial gave one group tirzepatide and the other semaglutide. Other semaglutide trials studied heart and kidney trouble. AOD-9604 lacks proved useful human weight loss; MOTS-c lacks proved human treatment benefit here.
Your choice needs both the benefit established by testing and the remaining questions about harm.